Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

We expect Fusion Pharmaceuticals (FUSN) to beat expectations when it reports fourth-quarter and full-year 2023 results later this month or early next month. In the last reported quarter, the company beat earnings expectations by 72.73%.Factors to NoteFusion Pharmaceuticals makes next-generation radiopharmaceuticals as precision medicines. It has a diversified pipeline of targeted alpha therapy (TAT) programs.Fusion has a collaboration with AstraZeneca (AZN) to jointly develop novel TATs and combination prog ...